Aardvark Therapeutics, Inc. (AARD)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.39-64.81%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Aardvark Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.686
Annual ending 2026-12-31
Revenue	—	300,000
EPS	—	-3.008
Annual ending 2027-12-31
Revenue	—	1.03M
EPS	—	-2.413

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient cash runway into late 2027	The company aims to maintain a cash runway into late 2027.	Intact	cash reserves fall below 60 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated as a late-2027 runway commitment in 2026-Q2. Management reported $73.9 million in cash, cash equivalents, and short-term investments at June 30, 2026, compared with $91.2 million at March 31, 2026, and projected operations into late 2027. The stated runway is supported by current cash, but the decline in cash indicates limited progress in preserving the balance. Delivery assessment Oct 24, 2026
Assess unblinded clinical data from HERO and OLE trials	A supporting condition in Aardvark Therapeutics, Inc.'s published investment case. The stated target is Complete assessment by Q3 2026.	Under Pressure	Assessment is delayed beyond Q3 2026	Trial terminated vs Q3 2026 target H.C. Wainwright cut price target citing trial termination; FDA hold lifted but data assessment is no longer feasible on schedule. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Resolve regulatory uncertainties surrounding ARD-101	A primary condition in Aardvark Therapeutics, Inc.'s published investment case. The stated target is Approval by mid-2027.	Improving	regulatory hold extends beyond mid-2027	FDA hold lifted (qualitative) FDA lifted clinical hold on Oct 22, 2026, reversing the May 2026 hold and regulatory uncertainty. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.41

$-3.26 → $-2.41 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.26	$1,026,000	8 / 6
2026-07-25	$-3.26	$1,026,000	8 / 6
2026-07-26	$-3.15	$1,026,000	9 / 6
2026-07-27	$-3.15	$1,026,000	9 / 6
2026-07-28	$-3.15	$1,026,000	9 / 6
2026-07-29	$-3.10	$0	9 / 10
2026-07-30	$-3.10	$0	9 / 10
2026-07-31	$-3.10	$0	9 / 10
2026-08-01	$-3.10	$0	9 / 10
2026-08-02	$-3.10	$0	9 / 10
2026-08-03	$-3.10	$0	9 / 10
2026-08-04	$-3.10	$0	9 / 10
2026-08-05	$-3.10	$0	9 / 10
2026-08-06	$-3.10	$0	9 / 10
2026-08-07	$-3.10	$0	9 / 10
2026-08-08	$-3.10	$0	9 / 10
2026-08-09	$-3.10	$0	9 / 10
2026-08-10	$-3.10	$0	9 / 10
2026-08-11	$-3.10	$0	9 / 10
2026-08-12	$-3.10	$0	9 / 10
2026-08-13	$-3.10	$0	9 / 10
2026-08-14	$-3.15	$1,026,000	9 / 6
2026-08-15	$-3.15	$1,026,000	9 / 6
2026-08-16	$-3.15	$1,026,000	9 / 6
2026-08-17	$-3.15	$1,026,000	9 / 6
2026-08-18	$-3.15	$1,026,000	9 / 6
2026-08-19	$-3.15	$1,026,000	9 / 6
2026-08-20	$-3.15	$1,026,000	9 / 6
2026-08-21	$-2.56	$1,026,000	9 / 6
2026-08-22	$-2.56	$1,026,000	9 / 6
2026-08-23	$-2.56	$1,026,000	9 / 6
2026-08-24	$-2.56	$1,026,000	9 / 6
2026-08-25	$-2.56	$1,026,000	9 / 6
2026-08-26	$-2.56	$1,026,000	9 / 6
2026-08-27	$-2.56	$1,026,000	9 / 6
2026-08-28	$-2.56	$1,026,000	9 / 6
2026-08-29	$-2.56	$1,026,000	9 / 6
2026-08-30	$-2.56	$1,026,000	9 / 6
2026-08-31	$-2.56	$1,026,000	9 / 6
2026-09-01	$-2.56	$1,026,000	9 / 6
2026-09-02	$-2.56	$1,026,000	9 / 6
2026-09-03	$-2.56	$1,026,000	9 / 6
2026-09-04	$-2.56	$1,026,000	9 / 6
2026-09-05	$-2.56	$1,026,000	9 / 6
2026-09-06	$-2.56	$1,026,000	9 / 6
2026-09-07	$-2.56	$1,026,000	9 / 6
2026-09-08	$-2.56	$1,026,000	9 / 6
2026-09-09	$-2.56	$1,026,000	9 / 6
2026-09-10	$-2.56	$1,026,000	9 / 6
2026-09-11	$-2.56	$1,026,000	9 / 6
2026-09-12	$-2.56	$1,026,000	9 / 6
2026-09-13	$-2.56	$1,026,000	9 / 6
2026-09-14	$-2.56	$1,026,000	9 / 6
2026-09-15	$-2.56	$1,026,000	9 / 6
2026-09-16	$-2.56	$1,026,000	9 / 6
2026-09-17	$-2.56	$1,026,000	9 / 6
2026-09-18	$-2.56	$1,026,000	9 / 6
2026-09-19	$-2.56	$1,026,000	9 / 6
2026-09-20	$-2.56	$1,026,000	9 / 6
2026-09-21	$-2.56	$1,026,000	9 / 6
2026-09-22	$-2.56	$1,026,000	9 / 6
2026-09-23	$-2.56	$1,026,000	9 / 6
2026-09-24	$-2.56	$1,026,000	9 / 6
2026-09-25	$-2.56	$1,026,000	9 / 6
2026-09-26	$-2.56	$1,026,000	9 / 6
2026-09-27	$-2.56	$1,026,000	9 / 6
2026-09-28	$-2.56	$1,026,000	9 / 6
2026-09-29	$-2.56	$1,026,000	9 / 6
2026-09-30	$-2.56	$1,026,000	9 / 6
2026-10-01	$-2.56	$1,026,000	9 / 6
2026-10-02	$-2.56	$1,026,000	9 / 6
2026-10-03	$-2.56	$1,026,000	9 / 6
2026-10-04	$-2.56	$1,026,000	9 / 6
2026-10-05	$-2.56	$1,026,000	9 / 6
2026-10-06	$-2.56	$1,026,000	9 / 6
2026-10-07	$-2.56	$1,026,000	9 / 6
2026-10-08	$-2.56	$1,026,000	9 / 6
2026-10-09	$-2.56	$1,026,000	9 / 6
2026-10-10	$-2.56	$1,026,000	9 / 6
2026-10-11	$-2.43	$1,026,000	9 / 6
2026-10-12	$-2.43	$1,026,000	8 / 5
2026-10-13	$-2.43	$1,026,000	8 / 5
2026-10-14	$-2.43	$1,026,000	8 / 5
2026-10-15	$-2.43	$1,026,000	8 / 5
2026-10-16	$-2.43	$1,026,000	8 / 5
2026-10-17	$-2.43	$1,026,000	8 / 5
2026-10-18	$-2.43	$1,026,000	8 / 5
2026-10-19	$-2.43	$1,026,000	8 / 5
2026-10-20	$-2.43	$1,026,000	8 / 5
2026-10-21	$-2.40	$1,026,000	9 / 5
2026-10-22	$-2.40	$1,026,000	9 / 5
2026-10-23	$-2.40	$1,026,000	9 / 5
2026-10-24	$-2.41	$1,026,000	8 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	4	2
2026-06-01	6	4	2
2026-07-01	6	4	2
2026-08-01	6	4	2
2026-09-01	6	4	2
2026-10-01	6	4	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 4 Hold · 2 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 23

$2.50New observation · no comparable prior

UBSOct 19

$4.00New observation · no comparable prior

$0$2.20$4.40

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain sufficient cash runway into late 2027Direct metric needs a verified mapping
Assess unblinded clinical data from HERO and OLE trialsPublished status: Under Pressure

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

4.5%Typical daily move · historical

Downside history

-91.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Aardvark Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage business, not an established earnings compounder. The multi-year thesis is in a watch state: management has completed its review of exploratory trial data, but clinical efficacy remains unestablished.

What's priced into Aardvark Therapeutics, Inc.

The valuation model indicates AARD is cheap versus peers, with a small expectations gap and medium confidence. That relative discount sits alongside losses and high risk, so it does not resolve the uncertainty around the clinical case.

What the fundamentals likely do

Near term, results may remain difficult to read as a measure of progress: reported revenue was limited, and the company is loss-making. Management projected cash to support operations into late 2027, but cash declined between the first and second quarters; the next call and any guidance change are important risks.

What Aardvark Therapeutics, Inc. hinges on

The multi-year view hinges on whether HERO and OLE data can establish clinical efficacy and guide a credible next step. Cash preservation and the late-2027 runway commitment also matter; weaker jobs data could weigh on cyclical and healthcare names, while continued strength from sector bellwethers could support sector momentum.